Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers

publication date: Jun 10, 2022

Chengdu Keymed Biosciences dosed the first patient in a China Phase I trial of a bispecific antibody that targets solid tumors. CM350,which was developed on Keymed’s proprietary Novel T cell engager platform, is the first GPC3xCD3 to start China trials. GPC3 expression is rarely found in normal human adult tissues but upregulated in many types of solid tumors including hepatocellular carcinoma along with lung, gastric and esophageal cancers. The Phase I trial will evaluate safety issues and preliminary antitumor activity of CM350 in patients with solid tumors. Keymed develops novel drugs for autoimmune diseases and cancer. More details....

Stock Symbol: (HK: 02162)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital